Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Author: Mita M. M.   Poplin E.   Britten C. D.   Tap W. D.   Rubin E. H.   Scott B. B.   Berk L.   Rivera V. M.   Loewy J. W.   Dodion P.   Haluska F.   Sarantopoulos J.   Mita A.   Tolcher A.  

Publisher: Oxford University Press

ISSN: 0923-7534

Source: Annals of Oncology, Vol.24, Iss.4, 2013-04, pp. : 1104-1111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content